Progression-free patients were randomly assigned with an interactive voice-response system by block ( size four ) randomisation ( @:@ ) to receive either bevacizumab and capecitabine or bevacizumab only ( bevacizumab @ mg/kg on day @ ; capecitabine @ mg/m ( @ ) twice per day on days @-@ , every @ weeks ) until progression , stratified by oestrogen receptor status ( positive vs negative ) , visceral metastases ( present vs absent ) , response status ( stable disease vs response vs non-measurable ) , and lactate dehydrogenase concentration ( @ vs > @upper limit of normal ) .